HAE · Haemonetics Corporation

Current Thesis

Haemonetics is a med-tech transition story, not a momentum name. The defining overhang CSL Plasma's decision to walk from its U.S. disposables supply pact was fully annualized in fiscal 2026, so fiscal 2027 becomes the first "clean comp" year where strong ex-CSL organic growth finally shows up in reported numbers. The 2026-06-05 Q4 print plus FY2027 guidance (+4-7% reported revenue, +3-6% organic, margin +50-100bps) confirms the drag is behind it. The open wound is Interventional Technologies: vascular closure and electrophysiology keep losing share, and that is what capped the post-earnings bid. Price has recovered roughly 40% off the $47.39 washout low to the mid-$60s/$70 zone, but there is no accelerating narrative, no peer cluster breaking out, and the sector is defensive. This is a turnaround bounce being re-rated toward a depressed analyst cluster a watch/probe, not a fat pitch.

Bull Case

• CSL drag fully lapped (2026-06-05 Q4 call): Q4 revenue $346M, +5% reported but +9% organic ex-CSL; full-year FY2026 Plasma was -2% reported yet +20% organic ex-CSL ($524M). FY2027 is the year reported growth re-couples to that underlying strength.
• FY2027 guide signals inflection (2026-06-05): +4-7% reported revenue, +3-6% organic, adjusted EPS growing broadly in line with revenue, ~80% FCF conversion, operating margin +50-100bps. After two years of "transition," the company is guiding back to growth.
• Hospital is the growth engine (FY2026): Hospital revenue $588M, +4% organic; management framed FY2026 as the "culmination of the long-range transformation plan" with TEG hemostasis leadership intact.
• Capital return shrinking the float: completed a $300M buyback retiring ~8.68% of shares outstanding a tailwind to EPS into the clean-comp year.
• Analyst targets sit well above spot even after cuts: Barrington Outperform $89 (2026-05-12, cut from $94), Baird Outperform $81 (cut from $99), BTIG Buy $85 (cut from $105). Consensus ~$76-81 vs. a ~$66-70 tape.

Bear Case

• Interventional Technologies is still bleeding (2026-06-05): Q4 vascular closure revenue -8%; MVP/MVP XL -6% in electrophysiology. Management's "80% of the FY2026 decline lapped or non-material" is a forward claim, not a result execution must show before the multiple re-rates.
• Sell-side confidence is broken, not just trimmed: Raymond James downgraded to Outperform from Strong Buy and pulled HAE from its Current Favorites list over IVT selling execution; JPMorgan went to Neutral citing weaker Hospital and IVT. Citigroup stayed Neutral with only a $70 target (2026-05-28).
• GAAP loss flags clean-up charges: Q4 GAAP net loss of $20.1M / -$0.44 vs. +$1.17 a year ago a writedown/impairment quarter, consistent with troubled IVT assets.
• No narrative velocity: diagnostics/life-science-tools is a MATURING theme; HAE is a slow defensive compounder in repair mode, not a tape that runs +20% in two weeks. Wrong archetype for aggressive sizing.

Setup & Price Structure

The June 5 Q4 print was the binary, and it has passed the next hard catalyst (Q1 FY2027) is ~early August, outside the 30-day window. Structurally, HAE collapsed from a 52-week high of $87.30 to a $47.39 low on the CSL/IVT washout, then built a base and recovered to ~$66-70 (June 4 ~$69.85; June 2 close $66.37). The live battle is the round-number/Citi-PT $70 shelf. A clean weekly hold above $70-72 opens a run at the dense $81-85 analyst cluster; failure to clear keeps it range-bound in the $60s. The recovery thesis depends on holding the rising base losing ~$60 on a weekly close would say the turnaround bid failed and the IVT overhang is winning. This is a base-breakout-retest situation, not an extended momentum leg; entry quality is "above $72 with conviction" or "on a hold of the base," not chasing into the $60s mid-range.

Catalyst Calendar (next 30 days)

• 2026-06-05 (passed): Q4 + FY2026 results and FY2027 guidance the binary is already digested; current tape is the reaction.
• ~Mid-June 2026 (est.): healthcare investor conference season (Goldman Sachs / Jefferies-type events) possible management appearances; soft catalyst for tone, not numbers.
• No hard binary in the 30-day window. Next earnings binary is Q1 FY2027, ~early August 2026 track that print for the first read on whether reported growth actually re-couples to the FY2027 guide and whether IVT/vascular closure stops declining.

What Would Change Our Mind

• Bullish flip: weekly close above ~$72 with vascular-closure revenue returning to flat/positive on the Q1 print → narrative shifts from "turnaround hope" to "growth confirmed," re-rate toward $81-85.
• Bearish flip / invalidation: weekly close below ~$60 (loses the post-$47 base), OR Q1 FY2027 organic guide cut below +3%, OR vascular closure declines worsening beyond -8% YoY any one says IVT share loss is structural and the transition story is stalling.
• Sizing discipline: defensive med-tech turnaround = probe sizing only until growth re-acceleration is in the numbers; no aggressive build without a clean base breakout AND an IVT stabilization datapoint.

Correlation Notes

• Plasma-collection peers: revenue is tied to plasma-fractionation demand (CSL Behring, Grifols, Takeda end-markets); CSL's in-sourcing of disposables is the single largest idiosyncratic driver and is now lapped.
• Hospital/interventional comps: vascular closure and EP exposure correlates loosely with Abbott, Boston Scientific, Edwards procedure-volume trends; HAE underperforms the group specifically on IVT execution, so it trades on company-specific repair, not sector beta.
• Factor profile: defensive small/mid-cap med-tech low correlation to the AI/semis momentum complex; behaves more like a healthcare value-recovery name, which is why it is a poor fit for an accelerating-narrative book and should be sized accordingly.

[Sources: SEC 8-K Q4 FY2026 earnings release (2026-06-05); Barchart Q4 earnings call highlights; TheStreet (CSL non-renewal); Investing.com/Baird, GuruFocus/Barrington, public.com analyst targets; stockanalysis.com / Morningstar quote data.]